Related Experiment Video
Updated: Aug 14, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models
Trevor Hay1, Helen Jenkins, Owen J Sansom
1School of Bioscience, Cardiff University, Cardiff, United Kingdom.
Abstract:
The genes encoding the BRCA1 and BRCA2 tumor suppressors are the most commonly mutated in human familial breast cancers. Both have separate roles in the maintenance of genomic stability through involvement in homologous recombination, an error-free process enabling cells to repair DNA double-strand breaks. We have previously shown that cre-mediated conditional deletion of Brca2 within the mouse small intestine sensitizes the tissue to DNA damage. Eventually, the tissue repopulates via stem cells in which recombination at the floxed Brca2 allele has not taken place. In this study, we have treated Brca2-deficient small intestine with a potent small-molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), an enzyme predominantly involved in the recognition of DNA single-strand breaks. Brca2 deficiency rendered otherwise normal cells exquisitely sensitive to PARP inhibition, resulting in very high levels of apoptosis as early as 6 hours after treatment, with evidence for repopulation of the tissue at 12 hours. Furthermore, the intestines of animals treated with serial injections of the inhibitor repopulated very rapidly in comparison with those from untreated mice. Our results represent the first in vivo demonstration that inhibition of PARP1 activity confers exquisite sensitivity to death in physiologically normal Brca2-deficient cells, suggesting that such a regimen may be extremely potent prophylactically in women heterozygous for the BRCA2 gene, as well as against established tumors lacking functional BRCA2.
Insights
PARP1 inhibition causes rapid cell death in Brca2-deficient cells, offering a potential new treatment strategy for BRCA2-related cancers and hereditary breast cancer.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- BRCA1 and BRCA2 genes are crucial tumor suppressors involved in DNA repair.
- Mutations in BRCA2 are common in familial breast cancers and impair genomic stability.
- Previous studies showed Brca2 deletion sensitizes mouse intestine to DNA damage.
Purpose of the Study:
- To investigate the effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition on Brca2-deficient mouse small intestine.
- To determine if PARP1 inhibition can induce cell death in normal Brca2-deficient cells.
Main Methods:
- Conditional deletion of Brca2 in mouse small intestine.
- Treatment of Brca2-deficient intestine with a PARP1 inhibitor.
- Assessment of cell death (apoptosis) and tissue repopulation.
Main Results:
- Brca2 deficiency made cells highly sensitive to PARP1 inhibition.
- High levels of apoptosis were observed as early as 6 hours post-treatment.
- Rapid tissue repopulation occurred in treated animals compared to controls.
Conclusions:
- PARP1 inhibition demonstrates potent cell-killing effects in Brca2-deficient cells in vivo.
- This strategy could be effective prophylactically for BRCA2 mutation carriers.
- The findings suggest a potential therapeutic approach for BRCA2-deficient tumors.
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Long-patch Base Excision Repair
Base Excision Repair
The first step of...

